Speaker Profile

Ph.D., MPH, Vice President Commercial Markets, Tempus Inc.

Biography
In her current role, Suzanne focuses on commercial strategy and growth for Tempus developing and executing partnerships with organizations to improve healthcare value and outcomes by leveraging molecular and clinical data. Value creation for commercial payers, benefit managers and group purchasing organizations is where she focuses. Dr. Belinson is especially interested in applications of data to power solutions for the transition to and management of value based care. Prior to Tempus, Dr. Belinson served as Executive Director, Clinical Markets, at the Blue Cross Blue Shield Association where she led the sales and market development as well as day to day operations of Evidence Street. Dr. Belinson received her bachelor’s degree from Cleveland State University, a Masters in Public Health from the University of Pittsburgh, and a PhD in Epidemiology from the University of North Carolina at Chapel Hill.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Keith Yamamoto, UCSF

Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support

Sessions:

  • Realizing the Promise of Precision Medicine Using Real-world Evidence
    Session Chair: Atul Butte, UCSF
    - James Wall, Stanford
    - Nancy A. Dreyer, IQVIA
    - Mark Laabs, RCRF
    - John Concato, FDA
    - Rhonda Cooper-DeHoff, University of Florida
  • Opportunities and Challenges in Using Real World Data (RWD)
    Session Chair: Vivek Rudrapatna, UCSF
    - Kathy Giacomini, UCSF
  • How Are Patient Data Revolutionizing Precision Medicine?
    Session Chair: Clara Lajonchere, UCLA
    - Sharon Terry, Genetic Alliance
    - Farid Vij ,Ciitizen
    - Latha Palaniappan, Stanford
  • Regulatory Requirements and Challenges for Using RWE
    Session Chair: Sheila Walcoff, Goldbug Strategies
  • Government Partnerships: California Initiative to Advance Precision Medicine
    Session Chair: Julianne McCall, California Initiative to Advance Precision Medicine
    - Pablo Tamayo, UCSD
    - George M. Slavich, UCLA
  • Leveraging RWE to Create Value
    Session Chair: Kathryn A. Phillips, UCSF
    - Phil Febbo, Illumina
    - Suzanne Belinson, Tempus
    - Patricia Deverka, UCSF
    - Stacey Dacosta Byfield, OptumLabs
  • The Past, Present, and Future of RWE
    Session Chair: Keith Yamamoto, UCSF
    - Matthew Porteus, Stanford